Literature DB >> 2849342

Increased concentrations of leukotrienes in bronchoalveolar lavage fluid of patients with ARDS or at risk for ARDS.

A H Stephenson1, A J Lonigro, T M Hyers, R O Webster, A A Fowler.   

Abstract

The sulfidopeptide leukotrienes (LT) C4 and D4 have been reported to promote the formation of pulmonary edema when administered into the pulmonary circulation of laboratory animals. As a first step in the evaluation of the hypothesis that these leukotrienes participate in the edema formation of the adult respiratory distress syndrome (ARDS), we investigated whether LTC4 and LTD4 were present in the bronchoalveolar lavage (BAL) fluid of patients with ARDS compared to nonsmoker control subjects and to patients with acute respiratory failure exhibiting no radiographic evidence of widespread pulmonary infiltrates but having a clinical predisposition for developing ARDS, i.e., the "at risk" group. Bronchoscopic lavage was performed with sterile 0.9% NaCl on 32 control subjects, nine patients with ARDS, and nine patients "at risk" for ARDS. Leukotrienes were measured in BAL fluid by radioimmunoassay after methanol extraction and HPLC purification of a 20-ml aliquot of the BAL sample. LTC4 and LTD4 (mean +/- SE) increased from 1.1 +/- 0.2 and 1.2 +/- 0.5 ng/lavage in the BAL fluid of control subjects to 6.3 +/- 2.3 and 20.1 +/- 5.9 ng/lavage in patients "at risk" for ARDS and to 12.5 +/- 3.0 and 30.5 +/- 7.8 ng/lavage in patients with ARDS, respectively. The sulfidopeptide LTs correlated with BAL fluid protein content. These results suggest that increased amounts of LTs in BAL fluid are a general finding in patients with ARDS and those "at risk" for ARDS.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2849342     DOI: 10.1164/ajrccm/138.3.714

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  23 in total

Review 1.  Pulmonary diseases other than asthma as potential targets for antileukotriene therapy.

Authors:  M Peters-Golden
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

Review 2.  The measurement of leukotrienes in human fluids.

Authors:  J Y Westcott
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

3.  Cysteinyl leukotrienes impair hypoxic pulmonary vasoconstriction in endotoxemic mice.

Authors:  Bodil Petersen; K Frank Austen; Kenneth D Bloch; Yukako Hotta; Fumito Ichinose; Yoshihide Kanaoka; Warren M Zapol
Journal:  Anesthesiology       Date:  2011-10       Impact factor: 7.892

4.  Omega-oxidized leukotriene B4 detected in the broncho-alveolar lavage fluid of patients with non-cardiogenic pulmonary edema, but not in those with cardiogenic edema.

Authors:  W Seeger; F Grimminger; M Barden; G Becker; J Lohmeyer; D Heinrich; H G Lasch
Journal:  Intensive Care Med       Date:  1991       Impact factor: 17.440

5.  Leukotriene B4 and asthma.

Authors:  P E Christie; N C Barnes
Journal:  Thorax       Date:  1996-12       Impact factor: 9.139

6.  Leukotrienes and ARDS.

Authors:  K L Brigham; J R Sheller
Journal:  Intensive Care Med       Date:  1989       Impact factor: 17.440

7.  Cytokine-induced neutrophil chemoattractant in a rat model of lipopolysaccharide-induced acute lung injury.

Authors:  H Yamasawa; Y Ishii; S Kitamura
Journal:  Inflammation       Date:  1999-06       Impact factor: 4.092

8.  Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis.

Authors:  J Wilborn; M Bailie; M Coffey; M Burdick; R Strieter; M Peters-Golden
Journal:  J Clin Invest       Date:  1996-04-15       Impact factor: 14.808

9.  Pharmacological profile of a novel, orally active leukotriene B4 antagonist, SM-15178.

Authors:  N Ohmi; C Tani; K Yamada; M Fukui
Journal:  Inflammation       Date:  1994-04       Impact factor: 4.092

10.  Comparative protection against rat intestinal reperfusion injury by a new inhibitor of sPLA2, COX-1 and COX-2 selective inhibitors, and an LTC4 receptor antagonist.

Authors:  Thiruma V Arumugam; Naomi Arnold; Lavinia M Proctor; Michelle Newman; Robert C Reid; Karl A Hansford; David P Fairlie; Ian A Shiels; Stephen M Taylor
Journal:  Br J Pharmacol       Date:  2003-07-29       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.